Sangamo Therapeutics Delisting May 5 After Missing Bid Price, Moves to OTCQB
Sangamo Therapeutics will be delisted from Nasdaq on May 5, 2026 after failing to meet the minimum bid price requirement and will begin trading on the OTCQB Venture Market under SGMO. The company plans to appeal the decision and pursue capital-raising and strategic partnerships to support operations.
1. Nasdaq Delisting Details
Sangamo Therapeutics will be delisted from the Nasdaq Capital Market at the open on May 5, 2026 after failing to meet the minimum bid price requirement. Its common stock has been approved to trade on the OTCQB Venture Market under the SGMO ticker on the same date.
2. Appeal and Strategic Plans
The company is filing an appeal of Nasdaq’s decision but acknowledges that the suspension of trading on the exchange will proceed as scheduled. Sangamo is exploring capital-raising opportunities and potential business development partnerships to strengthen its financial position.
3. Investor Implications
Transitioning to OTCQB may reduce trading liquidity, widen bid-ask spreads and lower institutional participation for SGMO shares. Investors will monitor Sangamo’s appeal outcome, execution of financing plans and post-transition trading behavior for signals on longer-term stock performance.